menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

What to Know About ESR1 Mutations in HR+/HER2- Metastatic Breast Cancer

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post SurveySkip straight to the post survey if you have already participated in this activity
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    ESR1 mutations are frequently acquired during aromatase inhibitor treatment for HR+/HER2- metastatic breast cancer, making liquid biopsy monitoring vital to identify endocrine resistance. Learn more about this acquired mutation and how it can impact treatment with Dr. Mariya Rozenblit, Assistant Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    ESR1 mutations are frequently acquired during aromatase inhibitor treatment for HR+/HER2- metastatic breast cancer, making liquid biopsy monitoring vital to identify endocrine resistance. Learn more about this acquired mutation and how it can impact treatment with Dr. Mariya Rozenblit, Assistant Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine.

Facebook Comments

Schedule15 Apr 2024